CNS-reactive CD4+ T-cell responses in patients with MS and healthy subjects
Antigen . | RRMS, n (%) . | PPMS, n (%) . | SPMS, n (%) . | Healthy, n (%) . |
|---|---|---|---|---|
| Whole MBP | 7 (41) | 10 (50) | 1 (17) | 5 (63) |
| MBP mix | 10 (59) | 12 (60) | 1 (17) | 7 (88) |
| PLP-mix 1 | 9 (53) | 8 (40) | 3 (50) | 3 (38) |
| PLP-mix 2 | 11 (65) | 9 (45) | 2 (33) | 5 (63) |
| MOG-1 | 7 (41) | 4 (20) | 0 (0) | 2 (25) |
| MOG-2 | 11 (65) | 5 (25) | 2 (33) | 4 (50) |
| MOBP | 8 (47) | 6 (30) | 2 (33) | 4 (50) |
| MAG-1 | 9 (53) | 10 (50) | 4 (67) | 3 (38) |
| MAG-2 | 5 (29) | 7 (35) | 2 (33) | 4 (50) |
| MAG-3 | 3 (18) | 6 (30) | 1 (17) | 2 (25) |
| OMGP-1 | 11 (65) | 12 (60) | 3 (50) | 4 (50) |
| OMGP-2 | 6 (35) | 9 (45) | 3 (50) | 7 (88) |
| CRAB | 2 (12) | 3 (15) | 1 (17) | 0 (0) |
| SB | 0 (0) | 4 (20) | 3 (50) | 1 (13) |
| CNP-1 | 7 (41) | 10 (50) | 4 (67) | 4 (50) |
| CNP-2 | 3 (18) | 2 (10) | 0 (0) | 1 (13) |
| SEB | 17 (100) | 20 (100) | 6 (100) | 8 (100) |
| Total patients | 17/17 (100) | 20/20† (100) | 6/6 (100) | 8/8 (100) |
| Total responses* | 102/255†‡ (40) | 107/300†‡ (36) | 31/90†‡ (34) | 51/120†‡ (43) |
Antigen . | RRMS, n (%) . | PPMS, n (%) . | SPMS, n (%) . | Healthy, n (%) . |
|---|---|---|---|---|
| Whole MBP | 7 (41) | 10 (50) | 1 (17) | 5 (63) |
| MBP mix | 10 (59) | 12 (60) | 1 (17) | 7 (88) |
| PLP-mix 1 | 9 (53) | 8 (40) | 3 (50) | 3 (38) |
| PLP-mix 2 | 11 (65) | 9 (45) | 2 (33) | 5 (63) |
| MOG-1 | 7 (41) | 4 (20) | 0 (0) | 2 (25) |
| MOG-2 | 11 (65) | 5 (25) | 2 (33) | 4 (50) |
| MOBP | 8 (47) | 6 (30) | 2 (33) | 4 (50) |
| MAG-1 | 9 (53) | 10 (50) | 4 (67) | 3 (38) |
| MAG-2 | 5 (29) | 7 (35) | 2 (33) | 4 (50) |
| MAG-3 | 3 (18) | 6 (30) | 1 (17) | 2 (25) |
| OMGP-1 | 11 (65) | 12 (60) | 3 (50) | 4 (50) |
| OMGP-2 | 6 (35) | 9 (45) | 3 (50) | 7 (88) |
| CRAB | 2 (12) | 3 (15) | 1 (17) | 0 (0) |
| SB | 0 (0) | 4 (20) | 3 (50) | 1 (13) |
| CNP-1 | 7 (41) | 10 (50) | 4 (67) | 4 (50) |
| CNP-2 | 3 (18) | 2 (10) | 0 (0) | 1 (13) |
| SEB | 17 (100) | 20 (100) | 6 (100) | 8 (100) |
| Total patients | 17/17 (100) | 20/20† (100) | 6/6 (100) | 8/8 (100) |
| Total responses* | 102/255†‡ (40) | 107/300†‡ (36) | 31/90†‡ (34) | 51/120†‡ (43) |
The table shows the number of subjects from each group exhibiting a positive CD4+ T cell response to the corresponding antigen (percentages are in parentheses). Total patient populations: RRMS, N = 17; PPMS, N = 20; SPMS, N = 6; and healthy subjects, N = 8.
Indicates the total number of positive responses to the peptide pools (of a possible 15 for each subject).
Significantly higher compared with CD8+ T-cell responses in Table 4 (P < .05).
No significant differences in CD4+ responses between different subject groups.